Medical Liability Insurance (Video) By Erik Leander Richard Anderson Society may debate whether "defensive medicine" exists -- but every doctor would tell you he practices it.
Hey, Pharma! It's Time for a Change By Stephen Ambrose Only half of pharmaceutical companies see consumerism as an opportunity. But that's EXACTLY where the growth lies.
How to Unlock Group Insurance Market By Denise Garth Group insurers still aren't scratching the surface of the market, but are some just one or two details away from unlocking it?
Our Real Problem With Drug Pricing By Pramod John Americans have the worst of all worlds: neither a single-payer system with explicit price controls nor a free and fair market.
Diabetes: Defining Moment of a Crisis By Daniel Miller Unless a widespread education and intervention campaign on diabetes takes place, we are looking at a disaster.
A Horror Story on Health Insurance By Daniel Miller The author gets caught in a maze after finding he is at severe risk of glaucoma and must act immediately or lose his eyesight.
The Start-Ups That Are Innovating in Life By Amy Radin Start-ups such as LifeDrip and Smart Asset are going after distribution, product, client experience, speed, productivity and more.
The Next Opioid Epidemic: Fentanyl By Mark Pew "The synthetic, opium-like drugs were so potent that six of the agents became ill after handling them. One fell into a coma."
Auto Insurance in an Existential Crisis By Stephen Applebaum Alan Demers The 125-year-old, $300 billion U.S. auto insurance industry is caught between runaway inflation and strained consumer wallets.
The Promise of Continuous Underwriting By Bill Deemer Bobby Touran Typically, a risk is underwritten, bound... and forgotten. But new streams of data and automation allow for continuous underwriting.
Convergence and the Insurance Ecosystem By Stephen Applebaum Alan Demers Companies must anticipate the future, innovate beyond their core and transform their capabilities as rapidly as technology allows.
Lemonade's 'Synthetic Agent' Nonsense By Matteo Carbone Desperate for growth, Lemonade produces another howler: A lender receiving a 16% interest rate is presented as a (synthetic) agent.